Nicardipine and adenosine "flush cocktail" to prevent no-reflow during rotational atherectomy

Cardiovascular Revascularization Medicine

Volumn 9, Issue 4, 2008, Pages 224-228

  Fischell, Tim A ^a   Haller, Scott ^a   Pulukurthy, Satyavardham ^a   Virk, Imran S ^a  

^a Borgess Heart Institute   (United States)

Author keywords

Adenosine; Atherectomy; Calcium channel blocking drugs; Coronary vasospasm; Nicardipine; No reflow

Indexed keywords

ADENOSINE; CREATINE KINASE; CREATINE KINASE MB; FIBRINOGEN RECEPTOR; GLYCERYL TRINITRATE; HEPARIN; NICARDIPINE;

AGED; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ROTATIONAL ATHERECTOMY;

ADENOSINE; AGED; ANTICOAGULANTS; ATHERECTOMY, CORONARY; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY STENOSIS; CREATINE KINASE; CREATINE KINASE, MB FORM; DRUG COMBINATIONS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NECROSIS; NICARDIPINE; NITROGLYCERIN; NO-REFLOW PHENOMENON; PROSPECTIVE STUDIES; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 53349141042     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2008.03.002     Document Type: Article

References (28)

1. Teirstein P.S., Warth D.C., Haq N., Jenkins N.S., McCowan L.C., Aubanel-Reidel P., and Morris N. High speed rotational coronary atherectomy for patients with diffuse coronary artery disease. J Am Coll Cardiol 18 (1991) 1694-1701
2. Morishima I., Sone T., Okumura K., et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients with treated percutaneous transluminal coronary angioplasty for the first myocardial infarction. J Am Coll Cardiol 36 (2001) 1202
3. Ellis S.G., Popma J.J., Buchbinder M., Franco I., Leon M.B., Kent K.M., Pichard A.D., Satler L.F., Topol E.J., and Whitlow P.L. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 89 (1994) 882-892
4. Kini A., Reich D., Marmur J.D., Mitre C.A., and Sharma S.K. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: results of the Rota ReoPro randomized trial. Am Heart J 142 6 (2001) 965-969
5. Prevosti L.G., Cook J.A., Unger E.F., Sheffield C.D., Almagor Y., Bartorelly A.L., and Leon M.B. Particulate debris from rotational atherectomy: size distribution and physiological effects. Circulation 82 Suppl II (1988) III-83 [Abstract]
6. Eeckout E., and Kern M.J. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 22 9 (2001) 729-739
7. Feld H., Schulhoff N., Lichstein E., et al. Direct angioplasty as primary treatment for acute myocardial infarction resulting in the "no-reflow" phenomenon predicts a high mortality rate. Circulation 86 Suppl I (1992) I-135 [Abstract]
8. Abbo K.M., Dooris M., Glazier S., et al. Features and outcomes of no-reflow after percutaneous coronary intervention. Am J Cardiol 75 12 (1995) 778-782
9. Rezkalla S.H., and Kloner R.A. No-reflow phenomenon. Circulation 105 (2002) 656-662
10. Piana R.N., Paik G.Y., Moscucci M., et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 89 (1994) 2514-2518
11. Weyrens F.J., Mooney J., Lesser J., and Mooney M.R. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 75 12 (1995) 849-850
12. Kaplan B.M., Benzuly K.H., Kinn J.W., et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 39 2 (1996) 113-118
13. Fischell T.A., Subraya R.G., Ashraf K., Carter A.J., Perry B., and Haller S.D. "Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q was MI during SVG interventions. J Invasive Cardiol 19 (2007) 58-62
14. Fischell T.A., Carter A.J., Foster M.T., et al. Reversal of "no-reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cath Cardiovasc Diagn 45 (1998) 360-365
15. Fischell T.A., and Lauer M.A. Prevention and management of "no-reflow" during coronary interventions. In: Nissen S., Popma J., and Kern M. (Eds). Cardiac Catheterization and Interventional Self-Assessment Program (CathSap II) (2001), American College of Cardiology Foundation, Bethesda (Md) 183-187
16. Michaels A.D., Appleby M., Otten M.H., et al. Pretreatment with intracoronary verapamil prior to percutaneous coronary intervention in saphenous vein graft lesions; Results of the randomized, controlled VAsodilator Prevention Of no-Reflow (VAPOR) trail. J Invas Cardiol 14 (2002) 299-302
17. Haller S., Ashraf K., and Fischell T.A. Intragraft nicardipine prophylaxis to prevent no reflow in triple-vessel, saphenous vein graft intervention. J Invasive Cardiol 17 6 (2005) 334-337
18. Pomerantz R.M., Kuntz R.E., Diver D.J., et al. Intracoronary verapamil for the treatment of distal microvascular coronary spasm following PTCA. Cath Cardiovasc Diagnosis 24 (1991) 283-285
19. The Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I findings: TIMI Study Group. N Engl J Med 312 (1985) 932-936
20. Kloner R.A., Ganote C.E., and Jennings R.B. The "no-reflow" phenomenon following temporary coronary occlusion in the dog. J Clin Invest 54 (1974) 1496-1508
21. Bates E.R., Krell M.J., Dean E.N., et al. Demonstration of the "no-reflow" phenomenon by digital coronary arteriography. Am J Cardiol 56 (1986) 177-178
22. Bass T.A., Williams D.O., Ho K.K.L., et al. Is an aggressive Rotablator strategy preferable to standard Rotablator strategy in patients with heavily calcified coronary lesions? A report from the STRATAS Trial. J Am Coll Cardiol 31 (1998) 378A
23. Nakaya H., and Kanno M. Effects of nicardipine, a new dihydropyridine vasodilator, on coronary circulation and ischemia-induced conduction delay in dogs. Arzneimittel-Forschung 32 6 (1982) 626-629
24. Fugit M.D., Rubal B.J., and Donovan D.J. Effects of intracoronary nicardipine, diltiazem, and verapamil on coronary blood flow. J Invasive Cardiol 12 2 (2000) 80-85
25. Whiting R.L., Dow R.J., Graham D.J., and Mroszczak E.J. An overview of the pharmacology and pharmacokinetics of nicardipine. Angiology 41 11 Pt 2 (1990) 987-991
26. Lambert C.R., and Pepine C.J. Effects of intravenous and intracoronary nicardipine. Am J Cardiol 64 15 (1989) 8H-15H
27. Henry P.D. Comparative pharmacology of calcium antagonists: nifedipine, verapamil, and diltiazem. Am J Cardiol 46 (1980) 1047-1058
28. Singh B.N., and Josephson M.A. Clinical pharmacology, pharmacokinetics and hemodynamic effect of nicardipine. Am Heart J 119 2 Pt 2 (1990) 427-434